Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Recruiting, any sponsor type, condition "Fabry"
By trial status
The same filters, counted in each status. Pick one to switch.
13 trials
Showing 1 to 13, recently updated first.
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseasePivotal-lookingRecruiting
Idorsia Pharmaceuticals Ltd.Industry
NCT07778667 · 16 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 13, 2029
Drug: Lucerastat · For: Fabry Disease
Sites: Birmingham, Alabama; Oakland, California; Gainesville, Florida · 16 sites in all
Amicus TherapeuticsIndustry
NCT06906367 · 450 participants (planned) · Start Feb 13, 2026 · Primary completion Jun 2032
Drug: migalastat HCl; ERT · For: Fabry Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; Atlanta, Georgia · 8 sites in all
Amicus TherapeuticsIndustry
NCT04252066 · 20 participants (planned) · Start Mar 18, 2025 · Primary completion Aug 2029
Drug: migalastat · For: Fabry Disease
Sites: Philadelphia, Pennsylvania
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsPivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT06904261 · 8 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 2027
Drug: Migalastat HCl 20 mg · For: Fabry Disease
Sites: Atlanta, Georgia; Minneapolis, Minnesota; Charlotte, North Carolina · 12 sites in all
UniQure Biopharma B.V.Industry
NCT06270316 · 20 participants (planned) · Start Jun 5, 2024 · Primary completion Dec 1, 2027
Drug: AMT-191 · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 10 sites in all
ShireTakeda (TAK)
NCT05067868 · 5 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 31, 2027
Drug: Replagal · For: Fabry Disease
Sites: Kolkata, India; New Delhi, India · 3 sites in all
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06328608 · 22 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2028
Drug: PRX-102 1 mg/kg every two weeks · For: Fabry Disease
Sites: Phoenix, Arizona; Atlanta, Georgia; Iowa City, Iowa · 12 sites in all
Chiesi ItaliaIndustry
NCT07109375 · 75 participants (planned) · Start Jun 15, 2026 · Primary completion Feb 2029
Drug: pegunigalsidase alfa · For: Fabry Disease
Sites: Arezzo, Italy; Bari, Italy; Bologna, Italy · 7 sites in all
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT05710692 · 16 participants (planned) · Start Aug 1, 2023 · Primary completion Oct 2027
Drug: PRX-102 1 mg/kg every 2 weeks; PRX-102 2 mg/kg every 4 weeks · For: Fabry Disease
Sites: Chikushino-shi, Japan; Sendai, Japan; Nishihara, Japan · 10 sites in all
- A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry PatientsRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06663358 · 100 participants (planned) · Start Nov 6, 2024 · Primary completion Nov 2029
Drug: Pegunigalsidase-alfa · For: Fabry Disease
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 10 sites in all
GC Biopharma CorpIndustry
NCT06858397 · 18 participants (planned) · Start May 14, 2025 · Primary completion Aug 30, 2028
Drug: HM15421/GC1134A · For: Fabry Disesase
Sites: Los Angeles, California; Kansas City, Kansas; Minneapolis, Minnesota · 10 sites in all
4D Molecular TherapeuticsIndustry
NCT05629559 · 18 participants (planned) · Start Oct 16, 2022 · Primary completion Jun 2026
Drug: 4D-310 · For: Fabry Disease
Sites: Melbourne, Australia; Perth, Australia; Westmead, Australia · 4 sites in all
- Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry DiseaseRecruiting
Mackay Memorial HospitalAcademic, hospital or other
NCT05698901 · 150 participants (planned) · Start Sep 19, 2023 · Primary completion Sep 30, 2026
Drug: Agalsidase beta · For: Fabry Disease
Sites: Taipei, Taiwan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.